Source: Seeking Alpha

Fulgent: Fulgent Genetics: Undervalued, CFO Buying, And Promising Drug Candidates Make It A Buy

Read full article »
Fulgent's Competitors | Fulgent's News | Fulgent's Financials
Stay up-to-date with the latest news on Fulgent
Annual Revenue
$100-500M
Employees
1.0-5.0K
Ming Hsieh's photo - Chairman & CEO of Fulgent

Chairman & CEO

Ming Hsieh

CEO Approval Rating

94/100

Read more
Stay up-to-date with the latest news on Fulgent